Stockreport

Entrada Therapeutics Reports Third Quarter 2022 Financial Results

Entrada Therapeutics, Inc.  (TRDA) 
PDF On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 for the potential treatment of patients with Duchenne mu [Read more]